<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1409-4142</journal-id>
<journal-title><![CDATA[Revista Costarricense de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. costarric. cardiol]]></abbrev-journal-title>
<issn>1409-4142</issn>
<publisher>
<publisher-name><![CDATA[Asociación Costarricense de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1409-41422018000400044</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cardiotoxicidad de los quimioterapéuticos tipo antraciclinas de la lista oficial de medicamentos de la Caja Costarricense del Seguro Social]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salas Segura]]></surname>
<given-names><![CDATA[Juliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Carvajal]]></surname>
<given-names><![CDATA[José Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital San Juan de Dios  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>20</volume>
<numero>2</numero>
<fpage>44</fpage>
<lpage>47</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S1409-41422018000400044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S1409-41422018000400044&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S1409-41422018000400044&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La cardiotoxicidad asociada al uso de quimioterapéuticos ha sido ampliamente corroborada a través de diversos estudios clínicos. En Costa Rica se han empezado a desarrollar Unidades Cardio-oncológicas en diversos centros médicos con el fin de detectar de manera precoz el efecto deletéreo cardiovascular asociado a los diferentes quimioterapéuticos. A continuación, se presenta un resumen de las manifestaciones clínicas cardiovasculares asociadas al uso de antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS)]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cardiotoxicity of anthracycline-type chemotherapeutics in the official list of medicines of the Caja Costarricense del Seguro Social Cardiotoxicity associated with the use of chemotherapy has been largely corroborated along multiple clinical trials. In Costa Rica, the development of Cardio-oncologic Units has begun recently in various medical centers with the purpose of achieving an early detection of the deleterious cardiovascular effect associated with different chemotherapeutics. This review consists of a summary of the clinical manifestations related to the use of anthracyclines available in the Costa Rican public health system.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[Cardiotoxicidiad]]></kwd>
<kwd lng="es"><![CDATA[Oncología]]></kwd>
<kwd lng="es"><![CDATA[Antraciclinas]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Cardiotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Oncology]]></kwd>
<kwd lng="en"><![CDATA[Anthracyclines]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adão]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[De Keulenaer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leite-Moreira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brás-Silva]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention]]></article-title>
<source><![CDATA[Rev Port Cardiol]]></source>
<year>2013</year>
<volume>32</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>395-409</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Caja Costarricense de Seguro Social</collab>
<source><![CDATA[Lista oficial de medicamentos]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenneman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sawyer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2016</year>
<volume>118</volume>
<page-range>1008-20</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tajiri]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Aonuma]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Sekine]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients]]></article-title>
<source><![CDATA[Jpn J Clin Oncol]]></source>
<year>2017</year>
<volume>47</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>678-82</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Neilan]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Scherrer-Crosbie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anthracycline- Induced Cardiomyopathy in Adults]]></article-title>
<source><![CDATA[Compr Physiol]]></source>
<year>2015</year>
<volume>5</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1517-40</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swain]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Whaley]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Ewer]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2003</year>
<volume>97</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2869</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ichikawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ghanefar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bayeva]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicity of doxorubicin is mediated through mitochondrialiron accumulation]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2014</year>
<volume>124</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>617-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[ZV]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Doxorubicin Blocks Cardiomyocyte Autophagic Flux by Inhibiting Lysosome Acidification]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>133</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1668</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Fernández]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>487-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardinale]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Martinoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2000</year>
<volume>36</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>517</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardinale]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2004</year>
<volume>109</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2749</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luminari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Montanini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2010</year>
<volume>21</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1492</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Felker]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Hare]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>342</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1077</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline- Based Chemotherapy]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2015</year>
<volume>116</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>442-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Plana]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Galderisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging]]></article-title>
<source><![CDATA[J Am Soc Echocardiog]]></source>
<year>2014</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>911-39</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
